Therapeutic Asset Ratings
423 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Shr-8068
Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
P1/2
CC
(40)
Shr-9839 For
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(40)
Shr-A1904
Cancer
Jiangsu HengRui Medicine Co., Ltd.
P1/2
CC
(40)
Shr-A1921 For
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(40)
Shr-A2009 For
Cancer
Shanghai Hengrui Pharmaceutical Co., Ltd.
P1/2
CC
(40)
SKB103
Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
P1/2
CC
(40)
SKB105
Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
P1/2
CC
(40)
snv4818
Cancer
Pikavation Therapeutics, Inc.
P1/2
CC
(40)
srp1020
Cancer
Shanghai SciBrunch Therapeutics Co., Ltd.
P1/2
CC
(40)
Star0602
Cancer
Marengo Therapeutics, Inc.
P1/2
CC
(40)
syh2051
Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1/2
CC
(40)
sys6002
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1/2
CC
(40)
sys6010
Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
P1/2
CC
(40)
sys6045
Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
P1/2
CC
(40)
Trifluridine/Tipiracil Hydrochloride Combination Agent Tas-102
Advanced Solid Tumors
Regeneron Pharmaceuticals
P1/2
CC
(40)
tt-702
Cancer
Cancer Research UK
P1/2
CC
(40)
Tub-030
Cancer
Tubulis GmbH
P1/2
CC
(40)
Tucidinostat
Cancer
Chinese PLA General Hospital
P1/2
CC
(40)
vib305 for
Cancer
Vibrant Sciences Limited
P1/2
CC
(40)
Wef-001
Cancer
Auricula Biosciences Inc.
P1/2
CC
(40)
wj22096
Cancer
Nanjing Jingao biomidical technology Co. Ltd.
P1/2
CC
(40)
xnw28012
Cancer
Evopoint Biosciences Inc.
P1/2
CC
(40)
Ysch-01
Advanced Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
P1/2
CC
(40)
Zoldonrasib
Cancer
Revolution Medicines, Inc.
P1/2
CC
(40)
Adct-901
Cancer
ADC Therapeutics S.A.
P1
C
(39)
Showing 176 to 200 of 423 assets
Previous
Page 8 of 17
Next
